GPRC5B Regulates Macrophage Activity
GPRC5B binds to the Prostaglandin Receptor and affects the immune response
A team of scientists led by Nina Wettschureck at the Max Planck Institute for Heart and Lung Research has succeeded in clarifying the function of a so-called orphan G-protein-coupled receptor. Orphan receptors are receptors whose function has not yet been deciphered. The Bad Nauheimer researchers have now found that the orphan receptor GPRC5B plays a crucial role in regulating macrophage activity. This discovery could provide important impulses for the development of new therapies against inflammatory diseases.

Macrophages are a specific type of white blood cell. In the immune response, they have the task of neutralizing pathogens and foreign substances as so-called phagocytes. Therefore, they play a central role in defending against pathogens. Their function is regulated by a complex interplay of various signaling molecules, known as inflammatory mediators. A dysregulation can lead to a weakened immune response but also to chronic inflammation.
GPRC5B- and Prostaglandin Receptor

The research group of Nina Wettschureck has now shown that a receptor with previously unknown function can regulate the potency of Prostaglandin E2: GPRC5B. This receptor binds to a receptor on the surface of macrophages, the Prostaglandin Receptor EP2.
This has a significant impact on its function. "If GPRC5B binds to the Prostaglandin Receptor EP2, it influences the function of the EP2 receptor and thereby inhibits the activation of the macrophages," says Wettschureck. "In a further experiment, we inhibited the interaction between GPRC5B and the Prostaglandin Receptor. As a result, the macrophages were more active and could, for example, better fight invading bacteria," explains Wettschureck. Jeonghyeon Kwon, first author of the study, adds:"We have also found out exactly how the two receptors interact. This is the basis for a therapeutic approach. We want to develop a drug that targets this regulatory interaction."
The hope is to develop a therapy that can more precisely target acute and chronic inflammatory diseases.